Riskpilot← Back to searchSign inGet full accessPharmasa Oy
OYDissolvedY-tunnus 2728266-9Ukonmäentie 2Retail sale of cosmetic and toilet articles · NACE 4775Est. 2015— employees
Revenue 2025
—
EBITDA margin
—
-197% vs 2024
Equity ratio
99.3%
Financial strength
Net profit 2025
EUR 12K
-19% vs 2024
| Revenue | — | — |
| EBITDA | EUR -3K | -197% |
| Net profit | EUR 12K | -19% |
| Total assets | EUR 663K | -6% |
| Equity | EUR 659K | -6% |
| Employees | — | — |
Legal name
Pharmasa Oy
Y-tunnus number
2728266-9
Legal form
Osakeyhtiö
NACE code
4775 · Retail sale of cosmetic and toilet articles
Founded
1. joulukuuta 2015
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on terveystuotteiden, lääkkeiden käyttöön tarvittavien välineiden ja tarvikkeiden, nikotiinivalmisteiden, luontaistuotteiden, elintarvikkeiden ja kosmeettisten valmisteiden ja muiden ne. vapaankaupan tuotteiden vähittäiskauppa, tukkukauppa, valmistus, maahantuonti ja maastavienti. Yhtiön toimialaan kuuluvat myös lääkehoidon tukipalvelut, kosmetologin palvelut konsultointi-ja koulutuspalvelut ja henkilöstövuokraus. Lisäksi yhtiön toimialaan kuuluvat kiinteistöjen ja maa-alueiden, osuuksien, osakkeiden ja muiden arvopapereiden ostaminen, hallitseminen ja myyminen.
Address
Ukonmäentie 2
Phone
+3580505920263
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 853 | 861 | 851 | 710 | 569 | 255 | 0 | — |
| Staff expenses | −1 | −1 | −1 | −1 | 1 | 1 | — | — |
| EBITDA | 188 | 173 | 160 | 173 | 977 | 463 | 3 | −3 |
| Depreciation & amort. | — | — | — | — | — | — | — | — |
| EBIT | 188 | 173 | 160 | 173 | 165 | 48 | −3 | −3 |
| Net financials | 0 | 0 | 0 | 0 | 0 | — | 2 | 5 |
| Profit before tax | 188 | 173 | 160 | 173 | 165 | 48 | 18 | 15 |
| Tax | 38 | 35 | 32 | 35 | 33 | 11 | 4 | −3 |
| Net profit | 150 | 138 | 128 | 139 | 132 | 37 | 15 | 12 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 465 | 557 | 654 | 730 | 805 | 750 | 708 | 663 |
| Equity | 415 | 520 | 606 | 696 | 773 | 748 | 703 | 659 |
| Long-term debt | — | — | — | — | — | — | — | — |
| Short-term debt | 51 | 36 | 47 | 33 | 32 | 1 | 5 | 4 |
| Total debt | 51 | 36 | 47 | 33 | 32 | 1 | 5 | 4 |
EBITDA margin
-317000.0%
This company
15.8%
Market median
-2006429% vs market
20182025
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20182025
Return on equity
1.8%
This company
18.4%
Market median
-90% vs market
20182025
Net profit margin
1185100.0%
This company
8.1%
Market median
+14630764% vs market
20182025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20182025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via PRH / YTJ · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EI Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
PJ | Audit | 2015 | — | — |
VJ Deputy Member | Deputy Member | 2015 | — | — |
JB Audit | Audit | 2022 | — | — |
TT Deputy auditor | Deputy auditor | 2022 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmasa Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eija Irmeli Nousiainen | Chief Executive Officer | 0 companies |
| Pekka Johannes Neuvonen | Audit | 0 companies |
| Vesa Jarmo Tapani Nousiainen | Deputy Member | 0 companies |
| Jan-Erik Björklöf | Audit | 0 companies |
| Timo Tapio Post | Deputy auditor | 0 companies |